PERRIGO COMPANY PLC: Confirms Patent Challenge For Generic Version Of Finacea® Foam, 15%

Perrigo Company plc issued the following announcement on Feb. 20.

Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has filed a Paragraph IV Abbreviated New Drug Application with the U.S. Food and Drug Administration for a generic version of Finacea® Foam (azelaic acid foam, 15%).

Following notification from Perrigo, Bayer AG filed a patent litigation suit asserting patents listed in the Orange Book for Finacea® Foam in the United States District Court for the District of Delaware on February 15, 2018. This action formally initiates the litigation process under the Hatch-Waxman Act.

Finacea® Foam, 15% is a topical prescription medicine used to treat the inflammatory papules (raised spots) and pustules (pimple-like bumps) of mild to moderate rosacea. Annual market sales for 2017 were $54 million.

Perrigo Executive Vice President and President Rx Pharmaceuticals John Wesolowski stated, "This filing is another example of the hard work done by our R&D and legal teams to develop new generic products that lower the cost of healthcare for patients, consumers and families."

Original source can be found here.

Want to get notified whenever we write about Perrigo Company plc ?
Next time we write about Perrigo Company plc, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.
Organizations in this story

Perrigo Company plc 2 Grand Canal Street Lower Dublin, County Dublin